- Home
- PRCT vs IMVT Comparison
PRCT vs IMVT Comparison
Compare PRCT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRCT
- IMVT
- Stock Information
- Founded
- PRCT 2009
- IMVT 2018
- Country
- PRCT United States
- IMVT United States
- Employees
- PRCT N/A
- IMVT N/A
- Industry
- PRCT Medical Specialities
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRCT Health Care
- IMVT Health Care
- Exchange
- PRCT Nasdaq
- IMVT Nasdaq
- Market Cap
- PRCT 3.2B
- IMVT 2.8B
- IPO Year
- PRCT 2021
- IMVT N/A
- Fundamental
- Price
- PRCT $60.22
- IMVT $15.80
- Analyst Decision
- PRCT Strong Buy
- IMVT Buy
- Analyst Count
- PRCT 7
- IMVT 10
- Target Price
- PRCT $90.00
- IMVT $40.14
- AVG Volume (30 Days)
- PRCT 819.9K
- IMVT 1.3M
- Earning Date
- PRCT 07-31-2025
- IMVT 08-05-2025
- Dividend Yield
- PRCT N/A
- IMVT N/A
- EPS Growth
- PRCT N/A
- IMVT N/A
- EPS
- PRCT N/A
- IMVT N/A
- Revenue
- PRCT $249,121,000.00
- IMVT N/A
- Revenue This Year
- PRCT $47.40
- IMVT N/A
- Revenue Next Year
- PRCT $31.55
- IMVT N/A
- P/E Ratio
- PRCT N/A
- IMVT N/A
- Revenue Growth
- PRCT 59.36
- IMVT N/A
- 52 Week Low
- PRCT $47.04
- IMVT $12.72
- 52 Week High
- PRCT $103.81
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- PRCT 52.43
- IMVT 53.39
- Support Level
- PRCT $58.34
- IMVT $15.11
- Resistance Level
- PRCT $61.43
- IMVT $17.08
- Average True Range (ATR)
- PRCT 2.61
- IMVT 0.76
- MACD
- PRCT -0.37
- IMVT -0.00
- Stochastic Oscillator
- PRCT 38.21
- IMVT 47.56
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.